Monoclonal antibodies are leading agents for therapeutic treatment of human diseases, but are limited in use by the paucity of clinically relevant models for validation. Sporadic canine tumours mimic the features of some human equivalents. Developing canine immunotherapeutics can be an approach for modeling human disease responses. Rituximab is a pioneering agent used to treat human hematological malignancies. Biologic mimics that target canine CD20 are just being developed by the biotechnology industry. Towards a comparative canine-human model system, we have developed a novel anti-CD20 monoclonal antibody (NCD1.2) that binds both human and canine CD20. NCD1.2 has a sub-nanomolar Kd as defined by an octet red binding assay. Using FACS, NCD1.2 binds to clinically derived canine cells including B-cells in peripheral blood and in different histotypes of B-cell lymphoma. Immunohistochemical staining of canine tissues indicates that the NCD1.2 binds to membrane localized cells in Diffuse Large B-cell lymphoma, Marginal Zone Lymphoma, and other canine B-cell lymphomas. We cloned the heavy and light chains of NCD1.2 from hybridomas to determine whether active scaffolds can be acquired as future biologics tools. The VH and VL genes from the hybridomas were cloned using degenerate primers and packaged as single chains (scFv) into a phage-display library. Surprisingly, we identified two scFv (scFv-3 and scFv-7) isolated from the hybridoma with bioactivity towards CD20. The two scFv had identical VH genes but different VL genes and identical CDR3s, indicating that at least two light chain mRNAs are encoded by NCD1.2 hybridoma cells. Both scFv-3 and scFv-7 were cloned into mammalian vectors for secretion in CHO cells and the antibodies were bioactive towards recombinant CD20 protein or peptide. The scFv-3 and scFv-7 were cloned into an ADEPT-CPG2 bioconjugate vector where bioactivity was retained when expressed in bacterial systems. These data identify a recombinant anti-CD20 scFv that might form a useful tool for evaluation in bioconjugate-directed anti-CD20 immunotherapies in comparative medicine.

Bahit Dar University College of Medicine and Health Sciences Department of Medical Biochemistry and Molecular Biology Bahir Dar Ethiopia

Dipartimento di Biomedicina Comparata e Alimentazione Italy

Dipartimento di Scienze Veterinarie e Sanità Pubblica Università degli Studi di Milano via Celoria 10 20133 Milano Italy

INSERM Unité 940 Institut de Génétique Moléculaire Université Paris 7 Hôpital St Louis 27 rue Juliette Dodu Paris France

Mologic Ltd Bedford Technology Park Thurleigh Bedford MK44 2YP United Kingdom

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute 656 53 Brno Czech Republic

University of Edinburgh Institute of Genetic and Molecular Medicine and School of Veterinary Medicine Edinburgh EH4 2XR United Kingdom

Zobrazit více v PubMed

Osburn B, Scott C, Gibbs P (2009) One world—one medicine—one health: emerging veterinary challenges and opportunities. Revue scientifique et technique 28: 481–486. PubMed

Calistri P, Iannetti S, M LD, Narcisi V, Cito F, et al. (2013) The components of 'One World—One Health' approach. Transboundary and emerging diseases 60 Suppl 2: 4–13. 10.1111/tbed.12145 PubMed DOI

van Helden PD, van Helden LS, Hoal EG (2013) One world, one health. Humans, animals and the environment are inextricably linked—a fact that needs to be remembered and exploited in our modern approach to health. EMBO reports 14: 497–501. 10.1038/embor.2013.61 PubMed DOI PMC

Torgerson PR (2013) One world health: socioeconomic burden and parasitic disease control priorities. Veterinary parasitology 195: 223–232. PubMed

Luengo-Fernandez R, Leal J, Gray A, Sullivan R (2013) Economic burden of cancer across the European Union: a population-based cost analysis. The lancet oncology 14: 1165–1174. 10.1016/S1470-2045(13)70442-X PubMed DOI

Mittra J, Tait J (2012) Analysing stratified medicine business models and value systems: innovation-regulation interactions. New biotechnology 29: 709–719. PubMed

Peldschus K, Ittrich H (2014) Magnetic resonance imaging of metastases in xenograft mouse models of cancer. Methods in molecular biology 1070: 213–222. 10.1007/978-1-4614-8244-4_16 PubMed DOI

Malaney P, Nicosia SV, Dave V (2014) One mouse, one patient paradigm: New avatars of personalized cancer therapy. Cancer letters 344: 1–12. 10.1016/j.canlet.2013.10.010 PubMed DOI PMC

Das Thakur M, Pryer NK, Singh M (2014) Mouse tumour models to guide drug development and identify resistance mechanisms. The Journal of pathology 232: 103–111. 10.1002/path.4285 PubMed DOI

Siolas D, Hannon GJ (2013) Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer research 73: 5315–5319. PubMed PMC

Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nature reviews Drug discovery 3: 711–715. PubMed

Porrello A, Cardelli P, Spugnini EP (2006) Oncology of companion animals as a model for humans. an overview of tumor histotypes. Journal of experimental & clinical cancer research: CR 25: 97–105. PubMed

Henry CJ, Bryan JN (2013) Not lost in translation: how study of diseases in our pets can benefit them and us. Missouri medicine 110: 216–219. PubMed PMC

Klopfleisch R, Lenze D, Hummel M, Gruber AD (2011) The metastatic cascade is reflected in the transcriptome of metastatic canine mammary carcinomas. Veterinary journal 190: 236–243. PubMed

Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F (2012) Canine tumors: a spontaneous animal model of human carcinogenesis. Translational research: the journal of laboratory and clinical medicine 159: 165–172. PubMed

Parker HG, Shearin AL, Ostrander EA (2010) Man's best friend becomes biology's best in show: genome analyses in the domestic dog. Annual review of genetics 44: 309–336. 10.1146/annurev-genet-102808-115200 PubMed DOI PMC

Shearin AL, Ostrander EA (2010) Canine morphology: hunting for genes and tracking mutations. PLoS biology 8: e1000310 10.1371/journal.pbio.1000310 PubMed DOI PMC

Ranieri G, Gadaleta CD, Patruno R, Zizzo N, Daidone MG, et al. (2013) A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Critical reviews in oncology/hematology 88: 187–197. 10.1016/j.critrevonc.2013.03.005 PubMed DOI

Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, et al. (2006) The dog as a cancer model. Nature biotechnology 24: 1065–1066. PubMed

Sinha G (2014) Companion therapeutics. Nature biotechnology 32: 12–14. 10.1038/nbt.2793 PubMed DOI

Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nature reviews Cancer 12: 278–287. 10.1038/nrc3236 PubMed DOI

Weiner LM, Surana R, Wang S (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature reviews Immunology 10: 317–327. 10.1038/nri2744 PubMed DOI PMC

Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F (2005) CD20: a target antigen for immunotherapy of autoimmune diseases. Autoimmunity reviews 4: 526–531. PubMed

Ernst JA, Li H, Kim HS, Nakamura GR, Yansura DG, et al. (2005) Isolation and characterization of the B-cell marker CD20. Biochemistry 44: 15150–15158. PubMed

Griffin MM, Morley N (2013) Rituximab in the treatment of non-Hodgkin's lymphoma—a critical evaluation of randomized controlled trials. Expert opinion on biological therapy 13: 803–811. 10.1517/14712598.2013.786698 PubMed DOI

Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, et al. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90: 2188–2195. PubMed

Chambers SA, Isenberg D (2005) Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 14: 210–214. PubMed

Sinha A, Bagga A (2013) Rituximab therapy in nephrotic syndrome: implications for patients' management. Nature reviews Nephrology 9: 154–169. 10.1038/nrneph.2012.289 PubMed DOI

Lee S, Ballow M (2010) Monoclonal antibodies and fusion proteins and their complications: targeting B cells in autoimmune diseases. The Journal of allergy and clinical immunology 125: 814–820. 10.1016/j.jaci.2010.02.025 PubMed DOI

Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E (2013) Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PloS one 8: e66308 10.1371/journal.pone.0066308 PubMed DOI PMC

Vo AA, Choi J, Cisneros K, Reinsmoen N, Haas M, et al. (2014) Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients. Transplantation. PubMed

Vital EM, Kay J, Emery P (2013) Rituximab biosimilars. Expert opinion on biological therapy 13: 1049–1062. 10.1517/14712598.2013.787064 PubMed DOI

Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, et al. (2011) Clinical radioimmunotherapy—the role of radiobiology. Nature reviews Clinical oncology 8: 720–734. 10.1038/nrclinonc.2011.160 PubMed DOI

Grillo-Lopez AJ (2002) Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert review of anticancer therapy 2: 485–493. PubMed

Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, et al. (2002) Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 99: 4336–4342. PubMed

Ito D, Frantz AM, Modiano JF (2014) Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. Veterinary immunology and immunopathology. PubMed PMC

Mudaliar MA, Haggart RD, Miele G, Sellar G, Tan KA, et al. (2013) Comparative gene expression profiling identifies common molecular signatures of NF-kappaB activation in canine and human diffuse large B cell lymphoma (DLBCL). PloS one 8: e72591 10.1371/journal.pone.0072591 PubMed DOI PMC

Ito D, Brewer S, Modiano JF, Beall MJ (2014) Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential. Leukemia & lymphoma. PubMed PMC

Lane DP, Lane EB (1981) A rapid antibody assay system for screening hybridoma cultures. Journal of immunological methods 47: 303–307. PubMed

Ferraresso S, Bresolin S, Arico A, Comazzi S, Gelain ME, et al. (2014) Epigenetic Silencing of TFPI-2 in Canine Diffuse Large B-Cell Lymphoma. PloS one 9: e92707 10.1371/journal.pone.0092707 PubMed DOI PMC

Poggi A, Miniscalco B, Morello E, Comazzi S, Gelain ME, et al. (2013) Flow cytometric evaluation of ki67 for the determination of malignancy grade in canine lymphoma. Veterinary and comparative oncology. PubMed

Comazzi S, Gelain ME (2011) Use of flow cytometric immunophenotyping to refine the cytological diagnosis of canine lymphoma. Veterinary journal 188: 149–155. PubMed

Nathan S, Li H, Mohamed R, Embi N (2002) Phage display of recombinant antibodies toward Burkholderia pseudomallei exotoxin. Journal of biochemistry, molecular biology, and biophysics: JBMBB: the official journal of the Federation of Asian and Oceanian Biochemists and Molecular Biologists 6: 45–53. PubMed

Bhatia J, Sharma SK, Chester KA, Pedley RB, Boden RW, et al. (2000) Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. International journal of cancer Journal international du cancer 85: 571–577. PubMed

Du J, Wang H, Zhong C, Peng B, Zhang M, et al. (2007) Structural basis for recognition of CD20 by therapeutic antibody Rituximab. The Journal of biological chemistry 282: 15073–15080. PubMed

Perosa F, Favoino E, Vicenti C, Guarnera A, Racanelli V, et al. (2009) Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes. Journal of immunology 182: 416–423. PubMed

Powers GA, Hudson PJ, Wheatcroft MP (2012) Design and production of multimeric antibody fragments, focused on diabodies with enhanced clinical efficacy. Methods in molecular biology 907: 699–712. 10.1007/978-1-61779-974-7_39 PubMed DOI

Bagshawe KD (2009) Targeting: the ADEPT story so far. Current drug targets 10: 152–157. PubMed

Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, et al. (1995) Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs. British journal of cancer 72: 1083–1088. PubMed PMC

Siller E, DeZwaan DC, Anderson JF, Freeman BC, Barral JM (2010) Slowing bacterial translation speed enhances eukaryotic protein folding efficiency. J Mol Biol 396: 1310–1318. PubMed

Milenic DE (2002) Monoclonal antibody-based therapy strategies: providing options for the cancer patient. Current pharmaceutical design 8: 1749–1764. PubMed

Ricart AD, Tolcher AW (2007) Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nature clinical practice Oncology 4: 245–255. PubMed

Tobinai K (2003) Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan. Cancer chemotherapy and pharmacology 52 Suppl 1: S90–96. PubMed

Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Fosmire SP, et al. (2005) CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Veterinary pathology 42: 468–476. PubMed

Nixon AE, Sexton DJ, Ladner RC (2014) Drugs derived from phage display: from candidate identification to clinical practice. MAbs 6: 73–85. PubMed PMC

Doerner A, Rhiel L, Zielonka S, Kolmar H (2014) Therapeutic antibody engineering by high efficiency cell screening. FEBS Lett 588: 278–287. 10.1016/j.febslet.2013.11.025 PubMed DOI

Eisenhardt SU, Schwarz M, Bassler N, Peter K (2007) Subtractive single-chain antibody (scFv) phage-display: tailoring phage-display for high specificity against function-specific conformations of cell membrane molecules. Nat Protoc 2: 3063–3073. PubMed

Yang J, Zhu H, Tan Z, He F, Sun X, et al. (2013) Comparison of two functional kappa light-chain transcripts amplified from a hybridoma. Biotechnol Appl Biochem 60: 289–297. 10.1002/bab.1080 PubMed DOI

Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody